Skip to Content

Votrient Approval History

FDA Approved: Yes (First approved October 19, 2009)
Brand name: Votrient
Generic name: pazopanib
Dosage form: Tablets
Company: GlaxoSmithKline
Treatment for: Renal Cell Carcinoma, Soft Tissue Sarcoma

Votrient (pazopanib) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma.

Development History and FDA Approval Process for Votrient

DateArticle
Apr 26, 2012Approval FDA Approves Votrient for Advanced Soft Tissue Sarcoma
Oct 19, 2009Approval FDA Approves GlaxoSmithKline’s Votrient for Advanced Renal Cell Cancer
Oct  5, 2009GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for Votrient

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide